40,820 Shares in Amneal Pharmaceuticals, Inc. $AMRX Purchased by NorthCrest Asset Manangement LLC

NorthCrest Asset Manangement LLC acquired a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 40,820 shares of the company’s stock, valued at approximately $519,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Comerica Bank lifted its position in shares of Amneal Pharmaceuticals by 186.7% during the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after buying an additional 1,957 shares in the last quarter. Exchange Traded Concepts LLC purchased a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $31,000. Focus Partners Wealth bought a new position in shares of Amneal Pharmaceuticals in the third quarter valued at approximately $42,000. Advisory Services Network LLC purchased a new stake in shares of Amneal Pharmaceuticals during the third quarter valued at approximately $50,000. Finally, Bellevue Group AG purchased a new stake in shares of Amneal Pharmaceuticals during the third quarter valued at approximately $79,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Analysts Set New Price Targets

AMRX has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Truist Financial raised their target price on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Zacks Research upgraded Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Friday, March 6th. Finally, Barclays initiated coverage on shares of Amneal Pharmaceuticals in a report on Monday, December 8th. They issued an “overweight” rating and a $15.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $14.20.

Amneal Pharmaceuticals Stock Up 1.6%

Shares of AMRX stock opened at $12.26 on Thursday. The firm has a market cap of $3.86 billion, a P/E ratio of 53.31 and a beta of 1.35. The company has a 50 day moving average of $13.64 and a 200-day moving average of $12.14. Amneal Pharmaceuticals, Inc. has a 12-month low of $6.68 and a 12-month high of $15.42.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.